Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

8.3K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.5K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.5K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

1.9K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Loss of miR-146a-5p contributes to ibrutinib resistance in mantle cell lymphoma.

Blood advances·2026
Same author

A murine proof-of-concept study of polatuzumab vedotin in combination with venetoclax in experimental therapy of BCL2-positive aggressive lymphomas.

Scientific reports·2026
Same author

Circulating tumour DNA as a predictor of survival of patients with diffuse large B-cell lymphoma in a daily practice.

British journal of haematology·2025
Same author

Antibody polymer drug conjugates with increased drug to antibody ratio: CD38-targeting nanomedicines for innovative therapy of relapsed lymphomas.

Journal of controlled release : official journal of the Controlled Release Society·2025
Same author

Determination of ADP/ATP translocase isoform ratios in malignancy and cellular senescence.

Molecular oncology·2025
Same author

Long-term adaptation of lymphoma cell lines to hypoxia is mediated by diverse molecular mechanisms that are targetable with specific inhibitors.

Cell death discovery·2025
Same journal

RETRACTED: Kim et al. The Angiogenesis Inhibitor ALS-L1023 from Lemon-Balm Leaves Attenuates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease Through Regulating the Visceral Adipose-Tissue Function. <i>Int. J. Mol. Sci.</i> 2017, <i>18</i>, 846.

International journal of molecular sciences·2026
Same journal

Correction: Mahmud et al. Thymoquinone Attenuates NF-κβ Signalling Activation in Retinal Pigment Epithelium Cells Under AMD-Mimicking Conditions. <i>Int. J. Mol. Sci.</i> 2025, <i>26</i>, 11473.

International journal of molecular sciences·2026
Same journal

Correction: Borovikov et al. The Twisting and Untwisting of Actin and Tropomyosin Filaments Are Involved in the Molecular Mechanisms of Muscle Contraction, and Their Disruption Can Result in Muscle Disorders. <i>Int. J. Mol. Sci</i>. 2025, <i>26</i>, 6705.

International journal of molecular sciences·2026
Same journal

Correction: Molagoda et al. Flavonoid Glycosides from <i>Ziziphus jujuba</i> var. <i>inermis</i> (Bunge) Rehder Seeds Inhibit α-Melanocyte-Stimulating Hormone-Mediated Melanogenesis. <i>Int. J. Mol. Sci.</i> 2021, <i>22</i>, 7701.

International journal of molecular sciences·2026
Same journal

Correction: Guo et al. Integrated Transcriptomic and Metabolomic Analysis Reveals the Molecular Regulatory Mechanism of Flavonoid Biosynthesis in Maize Roots Under Lead Stress. <i>Int. J. Mol. Sci.</i> 2024, <i>25</i>, 6050.

International journal of molecular sciences·2026
Same journal

Correction: Chang et al. Improvement of Carbon Tetrachloride-Induced Acute Hepatic Failure by Transplantation of Induced Pluripotent Stem Cells Without Reprogramming Factor c-Myc. <i>Int. J. Mol. Sci.</i> 2012, <i>13</i>, 3598-3617.

International journal of molecular sciences·2026
See all related articles

Related Experiment Video

Updated: Oct 18, 2025

Ex vivo Mimicry of Normal and Abnormal Human Hematopoiesis
11:50

Ex vivo Mimicry of Normal and Abnormal Human Hematopoiesis

Published on: April 10, 2012

15.6K

BH3 Mimetics in Hematologic Malignancies.

Pavel Klener1,2, Dana Sovilj3, Nicol Renesova2

  • 1First Department of Internal Medicine‑Hematology, General University Hospital in Prague, 121 08 Prague, Czech Republic.

International Journal of Molecular Sciences
|September 28, 2021
PubMed
Summary
This summary is machine-generated.

Novel BH3 mimetics, like venetoclax, offer new hope for hematologic malignancies (HM) by directly targeting mitochondria. These agents show promise in overcoming chemotherapy resistance and improving patient outcomes in various blood cancers.

Keywords:
BH3 mimeticsapoptosisbiomarkershematologic malignanciesresistancetargeted therapyvenetoclax

More Related Videos

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
11:25

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Published on: April 1, 2015

13.5K
A Human Bone Marrow 3D Model to Investigate the Dynamics and Interactions Between Resident Cells in Physiological or Tumoral Contexts
09:07

A Human Bone Marrow 3D Model to Investigate the Dynamics and Interactions Between Resident Cells in Physiological or Tumoral Contexts

Published on: December 16, 2022

3.4K

Related Experiment Videos

Last Updated: Oct 18, 2025

Ex vivo Mimicry of Normal and Abnormal Human Hematopoiesis
11:50

Ex vivo Mimicry of Normal and Abnormal Human Hematopoiesis

Published on: April 10, 2012

15.6K
Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
11:25

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Published on: April 1, 2015

13.5K
A Human Bone Marrow 3D Model to Investigate the Dynamics and Interactions Between Resident Cells in Physiological or Tumoral Contexts
09:07

A Human Bone Marrow 3D Model to Investigate the Dynamics and Interactions Between Resident Cells in Physiological or Tumoral Contexts

Published on: December 16, 2022

3.4K

Area of Science:

  • Oncology
  • Hematology
  • Molecular Biology

Background:

  • Hematologic malignancies (HM) encompass diverse blood cancers, with relapses often linked to DNA damage response defects and anti-apoptotic blocks.
  • Current frontline therapies for many HM rely on classical cytostatics, leading to chemotherapy-refractory disease in a significant patient subset.
  • The TP53 tumor suppressor and BCL2 family proteins are frequently implicated in HM pathogenesis and treatment resistance.

Purpose of the Study:

  • To review the emerging role of BH3 mimetics as a novel therapeutic strategy for hematologic malignancies.
  • To highlight the mechanism of action of BH3 mimetics, particularly their ability to target mitochondria independently of TP53 status.
  • To discuss the clinical development of BH3 mimetics, including venetoclax and MCL1 inhibitors, and their potential impact on patient outcomes.

Main Methods:

  • Review of current literature on hematologic malignancies, treatment resistance mechanisms, and the development of BH3 mimetics.
  • Analysis of the mechanism of action of BCL2 homology 3 (BH3) mimetics, focusing on their pro-apoptotic effects.
  • Examination of ongoing clinical trials involving venetoclax and other BH3 mimetics in various HM.

Main Results:

  • BH3 mimetics, such as venetoclax, demonstrate potent anti-cancer activity by directly inducing apoptosis through mitochondrial targeting.
  • These agents are effective against non-dividing malignant cells and can overcome resistance associated with TP53 aberrations and anti-apoptotic protein overexpression.
  • Venetoclax is approved for CLL and AML, and numerous clinical trials are evaluating its efficacy in combination regimens and the potential of next-generation inhibitors.

Conclusions:

  • BH3 mimetics represent a promising new class of anti-cancer agents for hematologic malignancies, offering an alternative to traditional chemotherapy.
  • Ongoing clinical trials are crucial for defining optimal use, efficacy, safety, and biomarkers for BH3 mimetic therapy in HM.
  • Harnessing the full potential of BH3 mimetics could significantly improve the management and survival of patients with aggressive hematologic cancers.